Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides

被引:167
作者
Agrawal, S [1 ]
机构
[1] Hybridon Inc, Milford, MA 01757 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION | 1999年 / 1489卷 / 01期
关键词
antisense; oligonucleotide; mixed-backbone oligonucleotide; pharmacokinetics; immune stimulation; CpG; pro-drug; antiviral;
D O I
10.1016/S0167-4781(99)00141-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The antisense approach is conceptually simple and elegant; to design an inhibitor of a specific mRNA, one needs only to know the sequence of the targeted mRNA and an appropriately modified complementary oligonucleotide. Of the many analogs of oligodeoxynucleotides explored as antisense agents, phosphorothioate analogs have been studied the most extensively. The use of phosphorothioate oligodeoxynucleotides as antisense agents in various studies have shown promising results. However, they have also indicated that quite often, biological effects observed could be solely or partly non-specific in nature. It is becoming clear that not all phosphorothioate oligodeoxynucleotides of varying length and base composition are the same, and important consideration should be given to maintain antisense mechanisms while identifying effective antisense oligonucleotides. In this review, I have summarized the progress made in my laboratory in understanding the specificity and mechanism of actions of phosphorothioate oligonucleotides and the rationale for designing second-generation mixed-backbone oligonucleotides. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:53 / 68
页数:16
相关论文
共 111 条
[31]   APTAMERIC INHIBITION OF P210(BCR-ABL) TYROSINE KINASE AUTOPHOSPHORYLATION BY OLIGODEOXYNUCLEOTIDES OF DEFINED SEQUENCE AND BACKBONE STRUCTURE [J].
BERGAN, R ;
CONNELL, Y ;
FAHMY, B ;
KYLE, E ;
NECKERS, L .
NUCLEIC ACIDS RESEARCH, 1994, 22 (11) :2150-2154
[32]  
BRANCH AD, 1998, TRENDS PHARMACOL SCI, V23, P39
[33]   IMMUNE STIMULATION BY AN ANTISENSE OLIGOMER COMPLEMENTARY TO THE REV GENE OF HIV-1 [J].
BRANDA, RF ;
MOORE, AL ;
MATHEWS, L ;
MCCORMACK, JJ ;
ZON, G .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (10) :2037-2043
[34]   Modulation of plasminogen activator inhibitor type-1 biosynthesis in vitro and in vivo with oligo(nucleoside phosphorothioate)s and related constructs [J].
Buczko, W ;
Cierniewski, C ;
Kobylanska, A ;
Koziolkiewicz, M ;
Okruszek, A ;
Pawlowska, Z ;
Pluskota, E ;
Stec, WJ .
PHARMACOLOGY & THERAPEUTICS, 1997, 76 (1-3) :161-175
[35]   THE ANTIPROLIFERATIVE ACTIVITY OF C-MYB AND C-MYC ANTISENSE OLIGONUCLEOTIDES IN SMOOTH-MUSCLE CELLS IS CAUSED BY A NONANTISENSE MECHANISM [J].
BURGESS, TL ;
FISHER, EF ;
ROSS, SL ;
BREADY, JV ;
QIAN, YX ;
BAYEWITCH, LA ;
COHEN, AM ;
HERRERA, CJ ;
HU, SSF ;
KRAMER, TB ;
LOTT, FD ;
MARTIN, FH ;
PIERCE, GF ;
SIMONET, L ;
FARRELL, CL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (09) :4051-4055
[36]  
CHEN H, 1998, ANTISENSE 98
[37]   Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage [J].
Chen, LH ;
Agrawal, S ;
Zhou, WQ ;
Zhang, RW ;
Chen, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (01) :195-200
[38]  
*CIB FDN, 1997, CIB FDN S OL THER AG
[39]  
Crooke S. T., 1998, Antisense Research and Application
[40]  
Crooke ST, 1996, J PHARMACOL EXP THER, V277, P923